The first two patients have been enrolled in Genesys Spine’s U.S. prospective SIros™ Lateral Sacroiliac Fusion Study. The system was launched in early 2020, following clearance in 2019.
The SIros Sacroiliac Joint Fusion System is intended for sacroiliac joint fusion for conditions including degenerative sacroiliitis and sacroiliac joint disruption. The system consists of 3D Printed implants designed to transfix the sacroiliac joint and minimize micromotion to enable bony fusion.
“The SIros system transfixes and stabilizes the SI joint to relieve pain, and we are confident it will be the preferred lateral solution. It is exciting to become part of the limited group of companies that have data to support the lateral SI joint fusion procedure. We are working with Talosix, our research partner and a leader in real world evidence, to conduct this study and anticipate presentation of the data in 2023,” said Genesys Spine’s Chief Strategy Officer, SI Fusion, Meredith Gavlick.
The first two patients have been enrolled in Genesys Spine's U.S. prospective SIros™ Lateral Sacroiliac Fusion Study. The system was launched in early 2020, following clearance in 2019.
The SIros Sacroiliac Joint Fusion System is intended for sacroiliac joint fusion for conditions including degenerative sacroiliitis and sacroiliac joint...
The first two patients have been enrolled in Genesys Spine’s U.S. prospective SIros™ Lateral Sacroiliac Fusion Study. The system was launched in early 2020, following clearance in 2019.
The SIros Sacroiliac Joint Fusion System is intended for sacroiliac joint fusion for conditions including degenerative sacroiliitis and sacroiliac joint disruption. The system consists of 3D Printed implants designed to transfix the sacroiliac joint and minimize micromotion to enable bony fusion.
“The SIros system transfixes and stabilizes the SI joint to relieve pain, and we are confident it will be the preferred lateral solution. It is exciting to become part of the limited group of companies that have data to support the lateral SI joint fusion procedure. We are working with Talosix, our research partner and a leader in real world evidence, to conduct this study and anticipate presentation of the data in 2023,” said Genesys Spine’s Chief Strategy Officer, SI Fusion, Meredith Gavlick.
Copy to clipboard 
